U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Primus Corporation dba Trinity Biotech - 607698 - 12/22/2022
  1. Warning Letters

CLOSEOUT LETTER

Primus Corporation dba Trinity Biotech MARCS-CMS 607698 —

Delivery Method:
VIA Electronic Mail
Product:
Medical Devices
Recipient:
Recipient Name
Ronan O'Caoimh
Recipient Title
President/CEO
Primus Corporation dba Trinity Biotech

Southern Cross Business Park
I D A Boghall Road
Bray
Co. Wicklow
Ireland

ronan.ocaoimh@trinitybiotech.com
josh.wcarsC_i,Arinitybiotech.com
Issuing Office:
Center for Devices and Radiological Health

United States

Secondary Issuing Offices

United States

Dear Mr. O'Caoimh:

The Food and Drug Administration has completed evaluation of your firm's corrective actions in response to our Warning Letter (CMS # 607698) issued on August 11, 2020. Based, on our evaluation, it appears that you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Melissa Michurski,
Director Compliance Branch
Office of Medical Device and Radiological Health Division 2

Back to Top